Juvederm Ultra Smile — Lip-Specific Hylacross HA Filler (2 x 0.55ml)

Juvederm Ultra Smile is Allergan’s lip-specific formulation — 24 mg/mL Hylacross-cross-linked HA + 0.3% lidocaine engineered specifically for lip body augmentation and perioral wrinkle correction. Volumising capacity 3/5. The soft consistency suits lip body placement and corner-of-mouth correction. 2 x 0.55 mL per box.

Juvederm Ultra Smile with Lidocaine (2 x 0.55ml) is manufactured by Allergan / AbbVie, a France-based medical device and pharmaceutical company established in 1948. The product is part of the Juvederm dermal filler range, which is distributed across multiple international markets. Regulatory status: CE 0459 · Class III Medical Device · Manufactured in France.

Juvederm Ultra Smile with Lidocaine (2 x 0.55ml) contains 24 mg/mL of cross-linked hyaluronic acid plus 0.3% (3 mg/mL) premixed lidocaine for injection comfort. The hyaluronic acid is non-animal, produced by bacterial fermentation and cross-linked using Allergan / AbbVie’s Patented Hylacross Cross-Linking Technology technology. Phosphate-buffered saline at near-physiological pH carries the gel.

Per Allergan / AbbVie’s clinical data, Juvederm Ultra Smile with Lidocaine (2 x 0.55ml) delivers Up to 12 months of correction depending on placement and patient factors. Duration depends on injection depth, dose, anatomical site, patient metabolism, and facial movement intensity. Mid dermis (lip-specific) placement typically delivers the longer end of the duration range.

Juvederm Ultra Smile with Lidocaine (2 x 0.55ml) is engineered for mid dermis (lip-specific) placement. The standard recommended needle is 30G 1/2″, supplied in the syringe blister pack. Some practitioners prefer a blunt-tip cannula of equivalent gauge for safer placement in highly vascular zones, particularly for deeper subcutaneous work.

Juvederm Ultra Smile with Lidocaine (2 x 0.55ml) regulatory status: CE 0459 · Class III Medical Device · Manufactured in France. The product’s KFDA registration in South Korea is the primary regulatory baseline. CE marking and other international approvals enable distribution in the EU and other regulated markets. US FDA status varies — buyers in regulated jurisdictions should verify approval scope before importation and clinical use.

Store Juvederm Ultra Smile with Lidocaine (2 x 0.55ml) between 2 °C and 25 °C in original packaging, away from direct sunlight. Do not freeze — freezing damages the HA gel structure. Shelf life is typically 24 months from the manufacturing date printed on the box when unopened. Once a syringe is opened, contents must be used immediately. Partial syringes cannot be retained for later use due to sterility risk.

No. Juvederm Ultra Smile with Lidocaine (2 x 0.55ml) uses non-animal hyaluronic acid produced by bacterial fermentation — the standard manufacturing approach for modern HA dermal fillers. The product contains no animal proteins or by-products, making it suitable for patients who avoid animal-derived medical products. The product is contraindicated in patients with severe allergies to gram-positive bacterial proteins (used in HA fermentation).

Yes — layered protocols combining different fillers are standard aesthetic practice. Juvederm Ultra Smile with Lidocaine (2 x 0.55ml) can be combined with other Korean or international HA fillers, neuromodulators (botulinum toxin), or biostimulators (PLLA, calcium hydroxylapatite) within a single session. Always wait the recommended interval between different injectable products and confirm biocompatibility per each manufacturer’s IFU.

Juvederm Ultra Smile uses 2 x 0.55 mL syringes (1.1 mL total) rather than the 1 mL standard because lip work requires smaller incremental dosing than facial wrinkle work. Practitioners typically inject 0.2-0.5 mL per lip, making 0.55 mL the convenient unit per treatment. The smaller syringe reduces waste from partial use and supports the precision required in this high-visibility anatomical zone. Both syringes in a box may be used in a single comprehensive lip session or split across two consultations within the syringe’s sterile lifespan.